|
The Scientific Advisory Board (SAB) was created in 2002 to provide ongoing, high-level scientific advice to IPM. IPM’s scientific agenda is based on a set of decision-making criteria first approved by the SAB in 2003. The original SAB did not meet regularly, but IPM staff consulted individuals and small groups of IPM members as appropriate to request their expertise in particular areas of microbicide research and/or drug development. IPM established an Executive Committee of its SAB to meet annually, beginning in 2006.
At the 2008 Executive Committee meeting, it was agreed that IPM would restructure the current SAB and its Executive Committee, and reconstitute the membership. Updated Terms of Reference were subsequently determined, as well as new SAB membership. The Executive Committee was dissolved, and as of 2009, the new SAB convenes annually.
IPM’s SAB is composed of members with expertise in drug development, HIV and ARV science, microbicide development, clinical evaluation, delivery system expertise, regulatory knowledge , and other relevant areas. IPM’s Board of Directors review, approve, and update as required the Terms of Reference for the SAB and are consulted on SAB composition and leadership. IPM staff provides SAB members, IPM’s Board of Directors and donors with updates on IPM’s work, including a comprehensive annual report on IPM’s science and product development program and related topics.
 |
| Scientific Advisory Board Members |
 |
 |
, Chair, Professor in Molecular Infection
St. George's Hospital Medical School University of London, UK |
| |
|
 |
, Professor
Department of Obstetrics and Gynaecology, College of Health Sciences, University of Zimbabwe |
| |
|
 |
, Director
Product Development, CONRAD, USA |
| |
|
 |
, Principal Investigator, MTN, Co-Principal Investigator
Magee-Womens Hospital University of Pittsburgh School of Medicine, USA |
| |
|
 |
, Director
Clinical Development-Reproductive Health, Population Council, USA |
| |
|
 |
, Medical Director
ReProtect, Inc., USA |
| |
|
 |
School of Public Health, Makerere University Kampala, Uganda |
|
 |
 |
, Senior Director
Nonclinical Safety Products, GlaxoSmithKline, UK |
| |
|
 |
, Chief
Sexual Transmission and Injection Drug Use Studies Section,
Centers for Disease Control, USA |
| |
|
 |
, Professor of Virology
University College London Medical School, UK |
| |
|
 |
, Epidemiologist, Bill & Melinda Gates Foundation |
| |
|
 |
, Director of Biostatistics
Family Health International, USA |
| |
|
 |
, Director
Global Clinical Development,
Tibotec BVBA, Belgium |
| |
|
 |
, Professor
Desmond Tutu Hiv-Research Centre, Faculty of Health Sciences/Medical School, South Africa |
| |
|
| |
|
|
 |